Saturday 17 October 2026
Export MOLN’s income statement to Excel — free account
Molecular Partners AG Sponsored ADR
MOLN Healthcare Biotechnology
In the quarter to June 2026, revenue fell 98.9%, EPS grew 34.3% and free cash flow grew 23.8%, each against the same quarter a year earlier.
3.56
0.09
−2.47%
Follow MOLN
Molecular Partners AG Sponsored ADR (MOLN) P/E ratio
Molecular Partners AG Sponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 6.2× (April 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 1.6× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2024 | 0.0× | — |
| Sep 2024 | 0.0× | — |
| Jun 2024 | 0.0× | — |
| Mar 2024 | 0.0× | — |
| 12 more quarters | Free account |
Against its own ten years
Low 0.0×
High 6.2×
Ten-year median
0.0×
Current reading's percentile
79
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NKTX Nkarta, Inc. compare | n/m |
| ALXO ALX Oncology Holdings Inc. compare | n/m |
| MSLE Satellos Bioscience Inc. compare | n/m |
| CDXS Codexis, Inc. compare | n/m |
| MOLN Molecular Partners AG Sponsored ADR | n/m |
| TARA Protara Therapeutics, Inc. compare | n/m |
| NBP NovaBridge Biosciences compare | n/m |
| CNTN Canton Strategic Holdings, Inc. compare | 9.0× |
| MENS Jyong Biotech Ltd. compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)